The global genomics services market size was estimated to be USD 29.37 billion in 2023 and is expected to reach at USD 164.4 billion by 2033 with a CAGR of 16.95% during the forecast period 2023-2033. Increasing demand for gene therapy, drug discovery, & personalized medicine, growing prevalence of cancer, rising demand for consumer genomics, surge in research & development activities, increasing technological advancements, growing focus on the development of novel diagnostic testing using genomics, rising launch of innovative products, and surge in development of advanced systems for the utility of genomics with collaborative efforts are the factors propelling the market growth.
Surge in development of advanced systems for the utility of genomics with collaborative efforts is predicted to boost the market growth during the forecast period. For instance, in April 2023, Bio-Rad Laboratories, Inc. made a strategic shift in their measurable residual disease (MRD) genomics research and partnered with several companies and institutions to develop the QX600™ Droplet Digital™ PCR System. This advanced system has received FDA clearance and offers a user-friendly workflow, the ability to detect six colors for measuring 12 targets per well, and robust data analysis capabilities.
By Product, Consumables & Reagents was the highest revenue-grossing segment in the global genomics services market in 2022 owing to increasing usage in genomic systems, surge in number of genomic tests performed, growing preference for personalized medicines, rising launch of NGS technology. For instance, in June 2022, PerkinElmer Inc. launched the BioQule NGS System, an automated benchtop solution designed specifically for next-generation sequencing (NGS). This system is intended for research use only and aims to streamline the library preparation process. Additionally, Service is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for expertise required for genomics, rising focus on core operations by the end user, growing adoption of Whole Genome Sequencing (WGS) & applications of sequence databases for disorder screening and prognosis.
By Technology, Sequencing was the highest revenue-grossing segment in the global genomics services market in 2022 owing to rising prevalence of cancer, growing demand for biomarker discovery, and increasing launch of advanced software. For instance, in March 2023, Illumina, Inc. released Connected Insights, an innovative cloud-based software that facilitates tertiary analysis of clinical next-generation sequencing data. This software is designed to support genomic profiling (CGP) for advanced tumors and whole-genome sequencing for rare diseases and other advanced applications. Additionally, PCR is predicted to grow at fastest CAGR during the forecast period owing to the growing applications of polymerase chain reaction (PCR) in research & forensic laboratories, surge in demand for advanced diagnostics, rising technological advancements, and increasing launch of novel technologies.
By Type, Functional genomics was the highest revenue-grossing segment in the global genomics services market in 2022 owing to increasing research & development activities attempting to understand a specific phenotypical form of an established disease condition, rising development of gene therapies for cancers on the basis of functional genomic technology, and surge in collaborations within market players. For instance, in June 2023, Myriad Genetics and The University of Texas MD Anderson Cancer Center have joined forces to collaborate on research focused on treatment selection and response for metastatic renal cell carcinoma. Their partnership will involve integrating Myriad's minimal residual disease testing platform, which is based on whole-genome sequencing, into the research efforts. Additionally, Pathway analysis is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of pathway analysis in developing next-generation therapeutics, growing demand for pathway-based analysis in clinical genomics & personalized therapies.
By Application, Drug discovery & development was the highest revenue-grossing segment in the global genomics services market in 2022 owing to the rising research & development activities on diseases including cancer & genetic disorders and increasing technological advancements. Additionally, Diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic diseases such as cancer & genetic disorders, rising focus on the development of diagnostic testing, growing demand for early disease diagnosis, and surge in initiatives by major market players. For instance, in April 2023, The Clinical Laboratory Evaluation Program of the New York State (NYS) Department of Health has granted certification to Intermountain Precision Genomics and Myriad Genetics, allowing them to provide solid tumor testing solutions to patients nationwide. Intermountain Precision Genomics offers TheraMap®, which is Myriad's Precise™ Tumor test, enabling the analysis of tumor DNA to detect cancer-causing gene mutations.
By End User, Pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global genomics services market in 2022 owing to the rising demand for use of genomics in drug discovery, growing adoption of spatial genomics & transcriptomics technologies, and increasing research & development activities. For instance, in June 2022, Illumina Inc. has announced its plan to showcase seven abstracts related to significant oncology research at the American Society of Clinical Oncology (ASCO) 2022. Additionally, they will host an event to discuss the transformative influence of comprehensive genomic profiling in precision medicine. Additionally, Hospitals & clinics is predicted to grow at fastest CAGR during the forecast period owing to the rising number of hospitals & clinics offering genomic sequencing services to patients and increasing usage of advanced technology in the daily practice of medicine.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of cancer, growing research & development activities, increasing adoption of advanced technologies for the utility of genomics with collaborative efforts, and surge in initiatives by key market players. For instance, In June 2023, BGI Genomics has introduced Genalive, an autonomous clinical laboratory established through a partnership between Tibbiyah Holding and BGI Almanahil Health for Medical Services, a subsidiary of BGI Genomics, in Saudi Arabia. Genalive will provide precision medicine solutions and comprehensive genetic testing using state-of-the-art sequencing platforms, AI-driven analytical tools, and advanced bioinformatics pipelines. This marks a significant milestone for BGI Genomics in its worldwide expansion of genetics research. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for genomics applications in diagnostics, increasing demand for novel therapeutic drugs, rising prevalence of various diseases, and surge in expansion by major market players. For instance, in February 2023, Eppendorf AG has increased its production capacity in China by securing a contract to construct a new manufacturing facility in Shanghai.
Surge in development of advanced systems for the utility of genomics with collaborative efforts is predicted to boost the market growth during the forecast period. For instance, in April 2023, Bio-Rad Laboratories, Inc. made a strategic shift in their measurable residual disease (MRD) genomics research and partnered with several companies and institutions to develop the QX600™ Droplet Digital™ PCR System. This advanced system has received FDA clearance and offers a user-friendly workflow, the ability to detect six colors for measuring 12 targets per well, and robust data analysis capabilities.
By Product, Consumables & Reagents was the highest revenue-grossing segment in the global genomics services market in 2022 owing to increasing usage in genomic systems, surge in number of genomic tests performed, growing preference for personalized medicines, rising launch of NGS technology. For instance, in June 2022, PerkinElmer Inc. launched the BioQule NGS System, an automated benchtop solution designed specifically for next-generation sequencing (NGS). This system is intended for research use only and aims to streamline the library preparation process. Additionally, Service is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for expertise required for genomics, rising focus on core operations by the end user, growing adoption of Whole Genome Sequencing (WGS) & applications of sequence databases for disorder screening and prognosis.
By Technology, Sequencing was the highest revenue-grossing segment in the global genomics services market in 2022 owing to rising prevalence of cancer, growing demand for biomarker discovery, and increasing launch of advanced software. For instance, in March 2023, Illumina, Inc. released Connected Insights, an innovative cloud-based software that facilitates tertiary analysis of clinical next-generation sequencing data. This software is designed to support genomic profiling (CGP) for advanced tumors and whole-genome sequencing for rare diseases and other advanced applications. Additionally, PCR is predicted to grow at fastest CAGR during the forecast period owing to the growing applications of polymerase chain reaction (PCR) in research & forensic laboratories, surge in demand for advanced diagnostics, rising technological advancements, and increasing launch of novel technologies.
By Type, Functional genomics was the highest revenue-grossing segment in the global genomics services market in 2022 owing to increasing research & development activities attempting to understand a specific phenotypical form of an established disease condition, rising development of gene therapies for cancers on the basis of functional genomic technology, and surge in collaborations within market players. For instance, in June 2023, Myriad Genetics and The University of Texas MD Anderson Cancer Center have joined forces to collaborate on research focused on treatment selection and response for metastatic renal cell carcinoma. Their partnership will involve integrating Myriad's minimal residual disease testing platform, which is based on whole-genome sequencing, into the research efforts. Additionally, Pathway analysis is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of pathway analysis in developing next-generation therapeutics, growing demand for pathway-based analysis in clinical genomics & personalized therapies.
By Application, Drug discovery & development was the highest revenue-grossing segment in the global genomics services market in 2022 owing to the rising research & development activities on diseases including cancer & genetic disorders and increasing technological advancements. Additionally, Diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic diseases such as cancer & genetic disorders, rising focus on the development of diagnostic testing, growing demand for early disease diagnosis, and surge in initiatives by major market players. For instance, in April 2023, The Clinical Laboratory Evaluation Program of the New York State (NYS) Department of Health has granted certification to Intermountain Precision Genomics and Myriad Genetics, allowing them to provide solid tumor testing solutions to patients nationwide. Intermountain Precision Genomics offers TheraMap®, which is Myriad's Precise™ Tumor test, enabling the analysis of tumor DNA to detect cancer-causing gene mutations.
By End User, Pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global genomics services market in 2022 owing to the rising demand for use of genomics in drug discovery, growing adoption of spatial genomics & transcriptomics technologies, and increasing research & development activities. For instance, in June 2022, Illumina Inc. has announced its plan to showcase seven abstracts related to significant oncology research at the American Society of Clinical Oncology (ASCO) 2022. Additionally, they will host an event to discuss the transformative influence of comprehensive genomic profiling in precision medicine. Additionally, Hospitals & clinics is predicted to grow at fastest CAGR during the forecast period owing to the rising number of hospitals & clinics offering genomic sequencing services to patients and increasing usage of advanced technology in the daily practice of medicine.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of cancer, growing research & development activities, increasing adoption of advanced technologies for the utility of genomics with collaborative efforts, and surge in initiatives by key market players. For instance, In June 2023, BGI Genomics has introduced Genalive, an autonomous clinical laboratory established through a partnership between Tibbiyah Holding and BGI Almanahil Health for Medical Services, a subsidiary of BGI Genomics, in Saudi Arabia. Genalive will provide precision medicine solutions and comprehensive genetic testing using state-of-the-art sequencing platforms, AI-driven analytical tools, and advanced bioinformatics pipelines. This marks a significant milestone for BGI Genomics in its worldwide expansion of genetics research. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for genomics applications in diagnostics, increasing demand for novel therapeutic drugs, rising prevalence of various diseases, and surge in expansion by major market players. For instance, in February 2023, Eppendorf AG has increased its production capacity in China by securing a contract to construct a new manufacturing facility in Shanghai.
Segmentation: Genomics Services Market Report 2022 - 2033
Genomics Services Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Instruments/Systems/Software
- Consumables & Reagents
Services
- Biomarker Translation Services
- Core Genomics Services
- NGS-Based Services
- Computational Services
- Others
Genomics Services Market Analysis & Forecast by Technology 2022 - 2033 (Revenue USD Bn)
- PCR
- Flow Cytometry
- Microarrays
- Sequencing
- Others
Genomics Services Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Epigenomics
- Functional Genomics
- Biomarker Discovery
- Pathway Analysis
- Others
Genomics Services Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Diagnostics
- Drug Discovery & Development
- Agriculture & Animal Research
- Others
Genomics Services Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- Clinical Research
- Hospitals & Clinics
- Academic & Government Institutes
- Others
Genomics Services Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Genomics Services Market: Product Estimates & Trend Analysis
8. Genomics Services Market: Technology Estimates & Trend Analysis
9. Genomics Services Market: Type Estimates & Trend Analysis
10. Genomics Services Market: Application Estimates & Trend Analysis
11. Genomics Services Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Genomics Services Market
14. Europe Global Genomics Services Market
15. Asia Pacific Global Genomics Services Market
16. Latin America Global Genomics Services Market
17. MEA Global Genomics Services Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Eppendorf AG
- Bio-Rad Laboratories Inc.
- BGI Genomics
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Illumina Inc.
- Eurofins Scientific
- Color Genomics Inc.
- Myriad Genetics Inc.
- Agilent Technologies
- Quest Diagnostics Incorporated
- QIAGEN N.V.
- GE Healthcare
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California Inc.
- Oxford Nanopore Technologies
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 29.37 Billion |
| Forecasted Market Value ( USD | $ 164.4 Billion |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
